Eli Lilly and Company (LLY)

NYSE: LLY · USD

$1,170

+54.22 (+4.9%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-08-06 02:00 UTC. Latest published research analyzed 2026-05-08 · historical · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh LLY analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-08

Our latest published analysis: LLY rated Strong Buy

LLY is rated Strong Buy at $974.96 versus the reconciled fair value midpoint of $1,465.75, implying +50.34% upside/downside. Confidence is separately disclosed at 88/100.

Fair value (mid)

$1,466 / share

$1,025 – $1,936

Upside to FV

+50.3%

from $1,170

Confidence

88/100

Moat

9/10

Market cap	$869.4B
Revenue (ttm)	79.7B
Net income (ttm)	26.7B
EPS (ttm)	$29.8
Shares out	891.7M
P/E (trailing)	39.3x
P/E (forward)	22.2x
Dividend	$6.92 (0.59%)
Volume	6,433,398
Beta	0.51
Price target	$1,280	+9.5%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 79.7B
Net income (ttm): 26.7B
EPS (ttm): $29.8
P/E (trailing): 39.3x
P/E (forward): 22.2x
Market cap: $869.4B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$28.32B	$28.54B	$34.12B	$45.04B	$65.18B	+23.2%
Gross profit	$21.01B	$21.91B	$27.04B	$36.63B	$54.13B	+26.7%
Operating income	$6.36B	$8.28B	$10.33B	$17.04B	$29.70B	+47.0%
Net income	$5.58B	$6.24B	$5.24B	$10.59B	$20.64B	+38.7%
EPS (diluted)	$6.14	$6.57	$5.80	$11.71	$22.95	+39.0%
EBITDA	$7.90B	$8.66B	$11.85B	$18.81B	$31.69B	+41.5%
R&D	$7.90B	$7.19B	$9.31B	$10.99B	$13.34B	+14.0%
SG&A	$6.43B	$6.44B	$7.40B	$8.59B	$11.09B	+14.6%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	30.6B	40.7x	6.4x	96.6%	+47.5%	-45.5%	Strong Buy
ANET	Arista Networks Inc.	248.9B	62.4x	23.6x	284.8%	+32.0%	+63.9%	Strong Buy
ARGX	argenx SE	54.1B	31.5x	10.2x	50.6%	+58.8%	+25.7%	Strong Buy
ABBV	AbbVie Inc.	435.1B	69.6x	6.8x	17.7%	+3.7%	+28.7%	Hold
ABT	Abbott Laboratories	182.9B	34.2x	3.9x	7.5%	+3.0%	-16.8%	Strong Buy
AMGN	Amgen Inc.	220.5B	25.3x	5.8x	20.2%	+8.4%	+39.1%	Strong Buy

All LLY indicators

Market & fundamental data

Available fields

274

Groups with data

Currency

USD

Showing 274 of 274 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000059478
Company name	Eli Lilly and Company
Country	United States
Country code	US
Cusip	532457108
Employees	50,000
Employees Change	3,000%
Employees Change Percent	6.38
Enterprise value	$1.1T
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500
Industry	Drug Manufacturers - General
Industry PE	31.36
Industry PE Fwd	17.85
Isin	US5324571083
Last refreshed	2026-08-06
Market cap	$1T
Market cap category	Mega-Cap
Price	$1,170
Price currency	USD
Rev Per Employee	1,593,320x
Sector	Healthcare
Sector PE	48.99
Sector PE Fwd	22.9
Sic	2834
Symbol	LLY
Tags	pharmaceuticals, weight-loss
Website	https://www.lilly.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.56%
EV Earnings	40.46x
EV Sales Forward	12.35x
EV/EBIT	32.14x
EV/EBITDA	30.25x
EV/FCF	91.42x
EV/Sales	13.57x
FCF yield	1.13%
Forward P/E	28.65x
P/B ratio	33.5x
P/E ratio	39.27x
P/S ratio	13.09x
PE Ratio10 Y	52.78x
PE Ratio3 Y	71.41x
PE Ratio5 Y	62.99x
PEG ratio	1.27x
PS Forward	11.92x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	42.22%
EBITDA Margin	44.85%
FCF margin	16.36%
Gross margin	83.4%
Gross Profit	$66.4B
Gross Profit Growth	50.96%
Gross Profit Growth Q	50.31%
Gross Profit Growth3 Y	42.51%
Gross Profit Growth5 Y	26.7%
Net Income	$26.7B
Net Income Growth	93.56%
Net Income Growth Q	25.34%
Net Income Growth Quarters	10%
Net Income Growth Years	2%
Net Income Growth3 Y	60.19%
Net Income Growth5 Y	34.49%
Pretax Margin	42.17%
Profit Margin	33.53%
Profit Per Employee	$534,220
Profitable Quarters	$10
Profitable Years	8
Roa5y	13.51
Roe5y	74.21
ROIC	45.45
Roic5y	35.51

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	32.51%
Cagr15y	29.08%
Cagr1y	53.25%
Cagr20y	19.74%
Cagr3y	38.52%
Cagr5y	36.12%
Div CAGR10	12.67%
Div CAGR3	15.25%
Div CAGR5	15.25%
EPS Growth	94.82
EPS Growth Q	26.22
EPS Growth Quarters	10
EPS Growth Years	2
EPS Growth3 Y	60.68
EPS Growth5 Y	34.97
FCF Growth	216.44%
FCF Growth3 Y	36.63%
FCF Growth5 Y	13.11%
OCF Growth	119.79%
OCF Growth10 Y	21.88%
OCF Growth3 Y	44.46%
OCF Growth5 Y	21.25%
Revenue Growth	49.58x
Revenue Growth Q	47.67x
Revenue Growth Quarters	12x
Revenue Growth Years	8x
Revenue Growth3 Y	39.23x
Revenue Growth5 Y	24.41x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	$5.3B
Debt	$43.4B
Debt EBITDA	$1.21
Debt Equity	$1.39
Debt FCF	$3.67
Equity	$31.2B
Interest Coverage	275.7
Net Cash	$-37.6B
Net Cash By Market Cap	$-3.61
Net Debt EBITDA	$1.05
Net Debt Equity	$1.21
Net Debt FCF	$3.18
Tangible Book Value	$17.7B
Tangible Book Value Per Share	$19.8
WACC	6.76

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.62%
Dividend Growth	15.34%
Dividend Growth Years	11%
Dividend per share	$6.92
Dividend Years	56
Dividend Yield	0.59%
Ex Div Date	2026-08-14
Last Dividend	$1.73
Payout Frequency	Quarterly
Payout Ratio	23.76%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	1,568.02%
1Y total return	53.2%
200-day SMA	1,029.5
3Y total return	165.87%
50-day SMA	1,153
50-day SMA vs 200-day SMA	50over200
5Y total return	367.24%
All Time High	1,249.5
All Time High Change	-6.37%
All Time High Date	2026-07-07
All Time Low	2.04
All Time Low Change	57,274.2%
All Time Low Date	1977-09-21
ATR	41.38
Beta	0.51
Beta1y	-0.08
Beta2y	0.52
Ch YTD	8.86
High	1,216.9
High52	1,249.5
High52 Date	2026-07-07
High52ch	-6.37%
Low	1,136.7
Low52	623.8
Low52 Date	2025-08-08
Low52ch	87.54%
Ma50ch	1.47%
Premarket Change Percent	5.01
Premarket Price	$1,172
Premarket Volume	351,182
Price vs 200-day SMA	13.63%
RSI	51.28
RSI Monthly	65.11
RSI Weekly	62.09
Sharpe ratio	1.2x
Sortino ratio	2.01
Total Return	1.21%
Tr YTD	9.23
Tr15y	4,504.01%
Tr1m	-3.63%
Tr1w	-3.32%
Tr3m	21.07%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	28
Analyst Count Top	18
Analyst Price Target Top	$1,323
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$8.84
Earnings EPS Estimate Growth	40.1
Earnings Revenue Estimate	20,435,691,712x
Earnings Revenue Estimate Growth	31.35x
Operating Income	$39.6B
Operating Income Growth	77.5
Operating Income Growth Q	74.81
Operating Income Growth3 Y	68.37
Operating Income Growth5 Y	38.93
Operating margin	49.72
Price target	$1,280
Price Target Change	$9.45
Price Target Change Top	$13.11

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	889,325,651%
Float Percent	99.73%
Net Borrowing	4,464,000,000
Shares Insiders	0.17%
Shares Institutions	89.1%
Shares Out	891,741,406
Shares Qo Q	-0.25%
Shares Yo Y	-0.62%
Short Float	1.16%
Short Ratio	3.34
Short Shares	1.15

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$11.2B
Adjusted OCF	19,847,000,000
Average Volume	2,594,324.7x
Bv Per Share	34.92
CAPEX	$-8.7B
Ch10y	1,319.4
Ch15y	3,164.1
Ch1m	-3.63
Ch1w	-3.32
Ch1y	52.13
Ch20y	1,979
Ch3m	20.86
Ch3y	160.3
Ch5y	345.7
Ch6m	5.67
Change	4.86%
Change From Open	-0.35
Close	1,115.7
Days Gap	5.23
Depreciation Amortization	2,073,500,000
Dollar Volume	7,526,174,984.3
Earnings Date	2026-08-05
Earnings Time	bmo
EBIT	$33.6B
EBITDA	$35.7B
EPS	$29.79
F Score	3
FCF	$11.8B
FCF EV Yield	1.09x
FCF Per Share	$13.26
Financing CF	-7,063,000,000
Fiscal Year End	December
Founded	1,876
Graham Number	152.98052
Graham Upside	-86.92
Income Tax	$6.9B
Investing CF	-11,535,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-08-05
Last Report Date	2026-06-30
Last Split Date	1997-10-16
Last Split Type	Forward
Last10k Filing Date	2026-02-12
Lynch Fair Value	$745
Lynch Upside	-36.34
Ma150	1,045.7
Ma150ch	11.88%
Ma20	1,172.6
Ma20ch	-0.23%
Net CF	2,189,000,000
Next Earnings Date	2026-10-29
Open	1,174
Optionable	Yes
P FCF Ratio	88.24
P FCF Ratio SBC	93.23
P OCF Ratio	50.94
P OCF Ratio SBC	52.56
Payment Date	2026-09-10
Position In Range	41.3
Post Close	1,169.9
Postmarket Change Percent	0.7
Postmarket Price	$1,178
Pre Close	1,115.7
Price Date	2026-08-05
Price EBITDA	$29.2
Ptbv Ratio	58.96
Relative Volume	2.48x
Revenue	79,666,000,000x
SBC By Revenue	0.88x
Share Based Comp	633,000,000
Tax By Revenue	8.64x
Tax Rate	20.49%
Tr20y	3,572.37%
Tr6m	6.03%
Us State	Indiana
Views	3,866
Volume	6,433,398

Frequently asked questions

About this LLY report

What is the latest published LLY stock rating?

Eli Lilly and Company is shown with strong buy in the latest published report, analyzed 2026-05-08. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full LLY analysis?

The full latest published report, analyzed 2026-05-08, lives at /stocks/LLY/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for LLY?

The latest published report analyzed 2026-05-08 frames LLY around USD 1,025 to USD 1,936. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the LLY page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-08). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Eli Lilly and Company (LLY)

Coverage state: Latest published research available

Generate a fresh LLY analysis

Our latest published analysis: LLY rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · LLY

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All LLY indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on LLY

Frequently asked questions